Novavax, Inc.
Description
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
About
CEO
Mr. John Charles Jacobs M.B.A.
Employees
1,543
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
700 Quince Orchard Road, Gaithersburg, MD 20878, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 10, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 8, 2025 | — | — | — | — |
| Feb 26, 2025 | — | — | — | — |
| Nov 12, 2024 | -0.83 | -0.76 | 0.07 | -8.43% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 6 |
| Average estimate | — | -0.49 | — | 0.11 |
| Low estimate | — | -0.49 | — | -1.65 |
| High estimate | — | -0.49 | — | 2.35 |
| Last year EPS | — | -1.05 | — | -1.27 |
[stock_revenue_estimate]
Growth estimates
Current qtr
55.210%
Next qtr. (Mar 2025)
53.330%
Current year
77.560%
Next year (Dec 2025)
138.060%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 556.38M | 1.60B | 197.58M | 22.39M | 18.66M |
| Cost of revenue | 343.77M | 902.64M | — | — | — |
| Gross profit | 212.61M | 696.31M | 197.58M | 22.39M | — |
| Operating expense | |||||
| Research & development | 737.50M | 1.24B | 2.53B | 747.03M | 113.84M |
| Selling general and admin | 468.95M | 488.69M | 298.36M | 145.29M | 34.42M |
| Other operating expenses | -427.32M | -382.92M | -948.71M | -453.21M | — |
| Operating income | -566.51M | -644.74M | -1.69B | -416.72M | -129.60M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 14.42M | 19.88M | 21.13M | 15.15M | 12.19M |
| Other income expense | 37.90M | 10.97M | -6.83M | 13.61M | 10.52M |
| Pretax income | -543.03M | -653.65M | -1.71B | -418.26M | -132.69M |
| Tax provision | 2.03M | 4.29M | 29.22M | — | — |
| Net income | -545.06M | -657.94M | -1.74B | -418.26M | -132.69M |
| Basic EPS | -5.41 | -8.42 | -23.44 | -7.27 | -5.51 |
| Diluted EPS | -5.41 | -8.42 | -23.44 | -7.27 | -5.51 |
| Basic average shares | 100.77M | 78.18M | 74.40M | 57.55M | 24.10M |
| Diluted average shares | 100.77M | 78.18M | 74.40M | 57.55M | 24.10M |
| EBITDA | -487.39M | -604.71M | -1.68B | -398.23M | -125.36M |
| Net income from continuing op. | -545.06M | -657.94M | -1.74B | -418.26M | -132.69M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.80B | 2.26B | 2.58B | 1.58B | 172.96M |
| Current assets | |||||
| Cash | — | — | 96.37M | 122.31M | 15.86M |
| Cash equivalents | — | — | 1.42B | 431.09M | 62.96M |
| Cash and cash equivalents | 568.51M | 1.34B | 1.52B | 553.40M | 78.82M |
| Other short term investments | — | — | — | 157.65M | — |
| Accounts receivable | 297.24M | 82.38M | 454.99M | 262.01M | 7.50M |
| Other receivables | — | — | — | — | — |
| Inventory | 41.70M | 36.68M | 8.87M | — | — |
| Prepaid assets | 70.30M | 160.77M | 120.03M | 171.60M | 3.60M |
| Restricted cash | 10.42M | 10.30M | 11.49M | 93.88M | 2.95M |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 155.73M | 76.37M | 44.62M | 9.66M | 4.38M |
| Non current assets | |||||
| Properties | 185.22M | 106.24M | 40.12M | — | — |
| Land and improvements | 102.92M | 101.34M | 83.53M | 79.10M | — |
| Machinery furniture equipment | 153.36M | 139.74M | 122.61M | 37.74M | 14.93M |
| Construction in progress | 76.16M | 81.57M | 35.11M | 71.23M | 448,000 |
| Leases | 48.31M | 18.90M | 10.28M | 9.68M | 9.09M |
| Accumulated depreciation | -74.97M | -47.29M | -25.80M | -17.79M | -13.02M |
| Goodwill | 254.91M | 252.66M | 262.96M | 276.48M | 107.89M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | 4.77M | 5.73M | 5.58M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 35.16M | 28.47M | 24.29M | 13.22M | 7.53M |
| Total liabilities | 2.51B | 2.89B | 2.93B | 955.27M | 358.97M |
| Current liabilities | |||||
| Accounts payable | 132.61M | 216.52M | 127.05M | 54.33M | 2.91M |
| Accrued expenses | 338.72M | 538.59M | 635.31M | 116.64M | 12.44M |
| Short term debt | 5.14M | 352.08M | 130.53M | 105.86M | 1.26M |
| Deferred revenue | 241.31M | 370.14M | 1.42B | 273.23M | 1.68M |
| Tax payable | — | — | — | — | — |
| Pensions | 55.95M | 52.57M | 38.42M | 20.75M | 7.50M |
| Other current liabilities | 861.41M | 930.06M | 36.06M | 8.86M | — |
| Non current liabilities | |||||
| Long term debt | 223.94M | 197.70M | 323.46M | 362.12M | 320.61M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 33.13M | 55.70M | 42.12M | 13.48M | 12.57M |
| Shareholders equity | |||||
| Common stock | 1.41M | 868,000 | 764,000 | 714,000 | 324,000 |
| Retained earnings | -4.82B | -4.28B | -3.62B | -1.87B | -1.43B |
| Other shareholders equity | 2.72M | -6.38M | -1.35M | 7.02M | -12.51M |
| Total shareholders equity | -716.93M | -634.08M | -351.67M | 627.21M | -186.02M |
| Additional paid in capital | 4.19B | 3.74B | 3.35B | 2.54B | 1.26B |
| Treasury stock | 92.27M | 90.66M | 85.10M | 41.81M | 2.58M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||||
| Net Income | -545.06M | -657.94M | -1.74B | -418.26M | -132.69M | -184.75M | -183.77M | -279.97M | -156.94M | -82.95M | -51.98M | -28.51M | -19.36M | -35.71M | -40.35M | -36.32M | -28.59M | -19.58M | -6.32M | -25.92M | -17.27M | -22.70M | -9.75M | -12.19M | -4.50M | -4.80M | -4.50M | -5.50M |
| Depreciation | 41.23M | 29.05M | 12.66M | 4.89M | 5.68M | 8.16M | 9.82M | 8.51M | 5.98M | 4.42M | 2.59M | 1.67M | 1.61M | 1.37M | 1.19M | 893,000 | 834,000 | 371,000 | 1.79M | 3.05M | 1.19M | 1.14M | 3.49M | 594,000 | 400,000 | 300,000 | 300,000 | 300,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 85.36M | 130.30M | 183.63M | 128.04M | 17.05M | 18.31M | 19.81M | 19.16M | 13.43M | 6.09M | 2.48M | 2.09M | 2.05M | 1.34M | 1.53M | 2.07M | 1.80M | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | -929,000 | -3.80M | 136.79M | 230.78M | 6.38M | -5.41M | 6.07M | 3.93M | 4.25M | 927,000 | 1.91M | 4.99M | -24,000 | -35,000 | 1.69M | 2.34M | 1.42M | 2.90M | 614,000 | 262,000 | — | 343,000 | — | — | -100,000 | 100,000 | -100,000 | 100,000 |
| Accounts Receivable | -274.44M | 249.17M | -183.39M | -422.69M | -4.20M | 1.21M | — | 2.07M | 8.48M | -3.82M | -3.87M | 1.22M | -3.75M | 204,000 | 32,000 | 438,000 | -298,000 | 2.68M | -17,000 | 720,000 | -261,000 | 1.92M | -2.99M | 220,000 | -200,000 | 100,000 | -200,000 | -200,000 |
| Accounts Payable | -378.81M | 913.40M | 600.33M | 163.16M | — | -6.74M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | 276.41M | -1.52B | 1.32B | 271.55M | -8.33M | -15.61M | -4.46M | -4.85M | -785,000 | 315,000 | -772,000 | -728,000 | 2.50M | -150,000 | 150,000 | 1,000 | 522,000 | -669,000 | 7,000 | -2.61M | -497,000 | -1.32M | 3.70M | -1.41M | 800,000 | 200,000 | — | 100,000 |
| Operating Cash Flow | -796.25M | -863.53M | 322.95M | -42.54M | -116.12M | -184.83M | -152.53M | -251.14M | -125.58M | -75.01M | -49.65M | -19.27M | -16.98M | -32.98M | -35.74M | -30.58M | -24.31M | -14.29M | -3.93M | -24.49M | -16.85M | -20.61M | -5.56M | -12.79M | -3.60M | -4.10M | -4.50M | -5.20M |
| Investing Activities | ||||||||||||||||||||||||||||
| Capital Expenditures | — | — | — | — | — | — | — | 11,000 | 18,000 | 39,000 | 116,000 | 324,000 | — | — | — | 121,000 | — | -1.41M | -42,000 | -1.61M | -1.92M | -9.66M | -2.34M | -831,000 | -600,000 | -200,000 | — | -100,000 |
| Net Intangibles | -5.04M | -3.93M | -2.99M | -149,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | -165.52M | — | — | — | — | — | — | 3.03M | — | — | — | — | — | — | — | — | — | — | — | -3.33M | -12.47M | -600,000 | — | — | — |
| Purchase of Investments | — | — | -2.17M | -363.20M | -17.48M | -120.15M | -218.05M | -356.56M | -228.52M | -176.47M | -14.75M | -48.65M | -2.08M | -38.72M | — | -15.65M | -94.99M | -121.55M | — | — | — | — | — | — | — | — | — | -500,000 |
| Sale of Investments | — | — | 159.81M | 205.56M | 39.50M | 150.12M | 258.20M | 402.78M | 225.52M | 53.87M | 33.78M | 20.41M | 21.24M | 19.00M | 3.10M | 49.77M | 121.61M | 56.25M | — | — | — | — | — | — | — | — | 500,000 | — |
| Investing Cash Flow | — | — | 157.64M | -323.16M | 40.35M | 29.97M | 40.16M | 46.23M | -2.98M | -122.57M | 22.18M | -27.92M | 19.15M | -19.72M | 3.10M | 34.24M | 26.62M | -66.71M | -42,000 | -1.61M | -1.92M | -9.66M | -5.67M | -13.38M | -1.40M | -400,000 | 300,000 | -800,000 |
| Financing Activities | ||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | 175.25M | — | — | — | — | — | 325.00M | — | — | 1.45M | 650,000 | — | — | — | 200,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -352.35M | -93.60M | -127.91M | -96.07M | — | — | -37,000 | -466,000 | -667,000 | -795,000 | -560,000 | -164,000 | -80,000 | -86,000 | -15.04M | -1.04M | -809,000 | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -3.59M | -5.26M | — | -39.09M | — | — | — | -48.49M | -126,000 | -173,000 | -1,000 | -756,000 | 50,000 | — | — | — | — | — | — | -15.01M | — | — | — | — | 100,000 | -500,000 | — | — |
| Financing Cash Flow | 4.31M | 325.63M | 436.95M | 940.29M | 97.39M | 100.06M | 63.39M | 276.05M | 203.48M | 106.93M | 129.54M | 53.73M | 10.95M | 23.00M | 26.30M | 15.62M | -809,000 | 57.61M | 21.06M | -9.93M | 44.09M | 2.93M | 5.41M | 17.67M | 4.30M | 1.20M | 5.40M | 2.00M |
| Other Cash Details | ||||||||||||||||||||||||||||
| End Cash Position | 583.81M | 1.35B | 1.53B | 648.74M | 82.18M | 81.96M | 135.43M | 179.26M | 93.11M | 32.34M | 119.47M | 17.40M | 14.10M | 8.06M | 38.76M | 26.94M | 4.35M | 7.16M | 31.89M | 17.88M | 27.63M | 3.01M | 20.05M | 14.86M | 700,000 | 1.00M | — | — |
| Income Tax Paid | 190,000 | 17.98M | 12.61M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 17.35M | 18.04M | 19.43M | 13.71M | 12.19M | 12.19M | 12.19M | 6.19M | 96,000 | 179,000 | 177,000 | 20,000 | — | — | 817,000 | 1.04M | 1.07M | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -772.77M | -508.92M | 265.46M | -97.16M | -138.48M | -186.20M | -148.67M | -276.97M | -144.36M | -74.28M | -51.14M | -22.57M | -24.24M | -34.41M | -33.58M | -30.00M | -28.70M | -16.22M | -5.92M | -31.71M | -19.57M | -30.73M | -6.90M | -10.88M | -3.70M | -3.80M | -4.20M | -3.40M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 4,859,054 | 41.79M | 3.03% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 4,098,889 | 35.25M | 2.56% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 4,035,958 | 34.71M | 2.52% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 3,812,558 | 32.79M | 2.38% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 2,403,403 | 20.67M | 1.50% |
| Vanguard Small-Cap Growth Index Fund | Sep 30, 2024 | 2,099,565 | 18.06M | 1.31% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 1,442,304 | 12.40M | 0.90% |
| iShares Biotechnology ETF | Nov 30, 2024 | 1,042,287 | 8.96M | 0.65% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 985,290 | 8.47M | 0.62% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 888,587 | 7.64M | 0.55% |
Article
Novavax (NVAX) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day.
Feb 4, 2025
Article
Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel.
Feb 4, 2025
Article
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.
Feb 4, 2025
